Multicellular living organisms and unmodified parts thereof and – Nonhuman animal – Transgenic nonhuman animal
Reexamination Certificate
2005-09-27
2005-09-27
Woitach, Joseph (Department: 1632)
Multicellular living organisms and unmodified parts thereof and
Nonhuman animal
Transgenic nonhuman animal
C800S003000
Reexamination Certificate
active
06949691
ABSTRACT:
An animal model is provided which is genetically engineered to express human serum albumin, and such animals may be advantageously used in assessing drugs, vaccines or other therapeutic compounds that may be used in humans. In addition, an animal model is provided which does not manufacture its own albumin and which has been injected with human serum albumin. Through the use of these animal models, drugs and other chemicals can be more accurately assessed in physiological environments that reflect the conditions to be expected in humans, and such models will be useful in assessing new drugs and evaluating toxic substances for potential dangers as carcinogens, mutagens, etc. Other applications include evaluating immunological properties of various albumin-engineered proteins which might be administered to humans as therapeutics or vaccines, and research of disease states, such as genetic diseases, to provide further insight in treating these diseases.
REFERENCES:
patent: 4736866 (1988-04-01), Leder et al.
patent: 4873191 (1989-10-01), Wagner et al.
patent: 5416017 (1995-05-01), Burton et al.
patent: 5631407 (1997-05-01), Racaniello et al.
patent: 5633076 (1997-05-01), DeBoer et al.
patent: 5741957 (1998-04-01), Deboer et al.
patent: 5767337 (1998-06-01), Roses et al.
patent: 5780594 (1998-07-01), Carter
patent: 5948609 (1999-09-01), Carter et al.
patent: 6194633 (2001-02-01), Koretzky et al.
patent: 6291243 (2001-09-01), Fogarty et al.
patent: WO 96/04376 (1996-02-01), None
McCreath, 2000, Nature, vol. 405, pp. 1066-1069.
Denning, Jun. 2001, Nature Biotechnology, vol. 19, pp. 559-562.
Dinnyes, 2002, Cloning and Stem Cells, vol. 4, pp. 81-90.
Polejaeva, I.A. 2001, Control of Pig Reproduction VI, Reproduction, Suppl. vol. 58, pp. 293-300.
Cameron, 1997, Molec. Biotech. vol. 7, pp. 253-265.
Niemann, 1997, Transg. Res. vol. 7, pp. 73-75.
Campbell and Wilmut, 1997, Theriogenology, vol. 47, pp. 63-72.
Dorland's Medical Dictionary, “animal model”, http://www.mercksource.com/pp/us/cns/cns_hl_dorlands.jspzQzpgzEzzSzppdocszSzuszSzcommonzSzdorlandszSzdorlandzSzdmd_m_17zPzhtm#1046148.
Overbeek, 1994, “Factors affecting transgenic animal production,” Transgenic animal technology, pp. 96-98.
Wall, 1996, Theriogenology, vol. 45, pp. 57-68.□□.
Houdebine, 1994, J. Biotech. vol. 34, pp. 269-287.
Kappell, 1992, Current Opionions in Biotechnology, vol. 3, pp. 548-553.□□.
Milici et al., “Transcytosis of Albumin in Capillary Endothelium”, The Journal of Cell Biology, vol. 105 (No. 6, Pt. 1), Dec. 1987, pp. 2603-2612.
Schnitzer et al., “Albumin interacts specifically with a 60-kDa microvascular endothelial glycoprotein”, Proc. Natl. Acad. Sci., vol. 85, Sep. 1988, pp. 6773-6777.
Nomura, “Practical Development of Genetically Engineered Animals as Human Disease Models”, Laboratory Animal Science, vol. 47, No. 2, Apr. 1997, pp. 113-117.
Bertoglio Valarie
New Century Pharmaceuticals Inc.
Schulman B. Aaron
Stitues & Harbison PLLC
Woitach Joseph
LandOfFree
Human albumin animal models for drug evaluation, toxicology... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human albumin animal models for drug evaluation, toxicology..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human albumin animal models for drug evaluation, toxicology... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3372930